GO:0031772 type 2 orexin receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0031772 (type 2 orexin receptor binding) is a molecular function describing the binding of a ligand to the type 2 orexin receptor (OX2R), a G-protein-coupled receptor.
• OX2R is activated by the neuropeptides orexin-A and orexin-B and couples to both pertussis toxin-sensitive and -insensitive G-proteins, unlike OX1R.
• The OX2R protein is widely distributed in the brain and peripheral tissues, as shown by autoradiography with the selective antagonist EMPA.
• Orexin-induced apoptosis is mediated specifically through the seven-transmembrane domain OX2R, linking this binding event to cell death pathways.
• New orexin 2 receptor modulators are being investigated using in silico and in vitro methods, highlighting the therapeutic relevance of this binding function.
• Dysregulation of orexin signaling is implicated in insomnia and other sleep disorders, making OX2R a target for emerging therapies.
Description
The Gene Ontology (GO) term GO:0031772, type 2 orexin receptor binding, defines the molecular function of binding to the type 2 orexin receptor (OX2R), also known as the type 2 hypocretin receptor. This binding event is the first step in a signaling cascade that regulates arousal, wakefulness, and energy homeostasis. The orexin system, comprising orexin-A and orexin-B peptides and their two receptors (OX1R and OX2R), is a critical modulator of sleep-wake states, and OX2R has emerged as a key therapeutic target for insomnia and related disorders. Understanding the precise molecular interactions of ligands with OX2R is essential for drug discovery and for elucidating the receptor's role in physiology and disease. OX2R is a class A G-protein-coupled receptor (GPCR) that couples to both pertussis toxin-sensitive (Gi/o) and -insensitive (Gq) G-proteins, a property that distinguishes it from OX1R, which couples exclusively to pertussis toxin-insensitive G-proteins. This dual coupling allows OX2R to activate multiple downstream signaling pathways, including calcium mobilization and inhibition of cAMP production. Recent molecular dynamics simulations have revealed non-canonical Gq activation by OX2R and the antagonist lemborexant, providing atomic-level insights into receptor activation and drug action. Given the clinical importance of orexin signaling, researchers are actively investigating OX2R modulators using in silico and in vitro approaches. The distribution of OX2R protein in the brain and peripheral tissues has been mapped using radiolabeled antagonists, offering a foundation for understanding its physiological roles. Moreover, OX2R-mediated signaling can induce apoptosis in certain cellular contexts, suggesting additional functions beyond neuromodulation. This article provides a comprehensive overview of GO:0031772, covering its definition, mechanism, key genes, disease associations, and research methods, with a focus on CRISPR-based models for functional studies.
type 2 orexin receptor binding At A Glance
| GO ID | GO:0031772 |
|---|---|
| GO term | type 2 orexin receptor binding |
| Ontology | molecular_function |
| Synonym | OX2 orexin receptor binding, type 2 hypocretin receptor binding, type 2 hypocretin receptor ligand |
| Major function | Binding to the type 2 orexin receptor (OX2R), initiating downstream signaling |
| Receptor | Type 2 orexin receptor (OX2R), a G-protein-coupled receptor |
| Ligands | Orexin-A, orexin-B, and synthetic modulators such as lemborexant |
| G-protein coupling | Couples to both pertussis toxin-sensitive and -insensitive G-proteins |
| Tissue distribution | Widely expressed in brain and peripheral tissues |
What Is GO:0031772?
Type 2 orexin receptor binding (GO:0031772) is a molecular function defined as the binding of a ligand to a type 2 orexin receptor (OX2R). This binding typically involves the endogenous neuropeptides orexin-A and orexin-B, but can also include synthetic agonists or antagonists. The term encompasses the physical interaction between any ligand and OX2R, leading to receptor activation or inhibition. It is a subtype of orexin receptor binding and is specific to the OX2R subtype, distinguishing it from binding to OX1R.
Why Is type 2 orexin receptor binding Important in Cell Biology?
Type 2 orexin receptor binding is critically important because it initiates signaling pathways that regulate sleep-wake cycles, arousal, and energy balance. Dysregulation of this binding event is associated with sleep disorders such as insomnia and narcolepsy, and OX2R is a validated target for therapeutic intervention. Furthermore, OX2R-mediated signaling can influence cell survival and apoptosis, implicating this binding function in broader physiological and pathological processes. Understanding the molecular details of ligand-OX2R interactions is essential for designing selective modulators with improved efficacy and safety profiles.
• Regulates sleep-wake states and arousal through orexin signaling.
• OX2R is a therapeutic target for insomnia, with antagonists like lemborexant approved or in development.
• Dual G-protein coupling allows OX2R to activate diverse signaling cascades.
• Orexin-induced apoptosis is mediated specifically via OX2R, linking binding to cell death.
• OX2R protein distribution in brain and periphery informs its physiological roles.
• New modulators are being discovered using in silico and in vitro screening.
• The SK-N-MC cell line expresses an orexin binding site distinct from OX1R, useful for pharmacological studies.
• Molecular dynamics simulations reveal non-canonical Gq activation by OX2R.
• OX2R binding is implicated in energy homeostasis and metabolic regulation.
• Understanding OX2R binding aids in developing treatments for sleep disorders and potentially other conditions.
Molecular Mechanism of type 2 orexin receptor binding
Ligand Recognition and Binding
In simple terms: The ligand docks into a pocket on the receptor, like a key fitting into a lock.
The binding of orexin-A or orexin-B to OX2R involves specific interactions within the receptor's transmembrane domain. Molecular dynamics simulations have shown that the receptor undergoes conformational changes upon ligand binding, leading to activation. The binding pocket accommodates the C-terminal region of orexin peptides, which is critical for receptor selectivity and activation.
G-protein Coupling and Activation
In simple terms: Once the ligand binds, the receptor activates G-proteins inside the cell, which then relay the signal.
OX2R couples to both pertussis toxin-sensitive (Gi/o) and -insensitive (Gq) G-proteins, enabling activation of multiple signaling pathways. This dual coupling is a hallmark of OX2R and distinguishes it from OX1R. Recent simulations have revealed a non-canonical Gq activation mechanism by OX2R, providing structural insights into how the receptor engages G-proteins.
Downstream Signaling Cascades
In simple terms: The activated G-proteins trigger a chain of events inside the cell, leading to changes in cell behavior.
Activation of OX2R leads to increased intracellular calcium and inhibition of cAMP production, depending on the G-protein subtype. These signaling events regulate neuronal excitability and neurotransmitter release, contributing to arousal and wakefulness. In some cellular contexts, OX2R activation can also induce apoptosis through mechanisms involving the seven-transmembrane domain of the receptor.
Receptor Regulation and Desensitization
In simple terms: After signaling, the receptor can be turned off or recycled to prevent overstimulation.
Like many GPCRs, OX2R undergoes desensitization and internalization following prolonged agonist exposure. This process is mediated by phosphorylation and arrestin recruitment, although specific details for OX2R are still being elucidated. Understanding these regulatory mechanisms is important for the development of drugs that target OX2R.
Key Genes Involved in GO:0031772 type 2 orexin receptor binding
The following genes and proteins are directly involved in type 2 orexin receptor binding and its downstream signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HCRTR2 | Encodes the type 2 orexin receptor (OX2R) | Primary receptor for orexin binding; target for insomnia drugs |
| HCRT | Encodes orexin-A and orexin-B prepropeptide | Endogenous ligands that bind OX2R |
| GNAQ | Encodes Gq alpha subunit | Mediates pertussis toxin-insensitive signaling from OX2R |
| GNAI1 | Encodes Gi alpha subunit | Mediates pertussis toxin-sensitive signaling from OX2R |
| GNAO1 | Encodes Go alpha subunit | Alternative pertussis toxin-sensitive G-protein for OX2R |
| ARRB1 | Beta-arrestin 1 | Potential regulator of OX2R desensitization |
| ARRB2 | Beta-arrestin 2 | Potential regulator of OX2R desensitization |
| GRK2 | G-protein-coupled receptor kinase 2 | Phosphorylates activated OX2R, promoting arrestin binding |
| GRK3 | G-protein-coupled receptor kinase 3 | Phosphorylates activated OX2R, promoting arrestin binding |
| PRKCA | Protein kinase C alpha | Downstream effector of Gq signaling from OX2R |
| PRKCB | Protein kinase C beta | Downstream effector of Gq signaling from OX2R |
| PLCB1 | Phospholipase C beta 1 | Produces IP3 and DAG upon OX2R activation |
| CACNA1C | Calcium channel, voltage-dependent, L type | Mediates calcium influx following OX2R activation |
| MAPK1 | Mitogen-activated protein kinase 1 | Downstream signaling node activated by OX2R |
| MAPK3 | Mitogen-activated protein kinase 3 | Downstream signaling node activated by OX2R |
| CASP3 | Caspase 3 | Executioner of apoptosis induced by OX2R activation |
| CASP9 | Caspase 9 | Initiator caspase in OX2R-mediated apoptosis |
How Is type 2 orexin receptor binding Regulated?
The binding of ligands to OX2R is regulated at multiple levels. Receptor expression levels can be modulated by transcriptional and post-transcriptional mechanisms, affecting the availability of binding sites. Ligand availability is controlled by the release of orexin peptides from hypothalamic neurons, which is influenced by circadian rhythms and metabolic state. At the receptor level, phosphorylation by G-protein-coupled receptor kinases (GRKs) and subsequent arrestin binding lead to desensitization and internalization, thereby regulating the duration and intensity of signaling. Additionally, allosteric modulators may influence the binding affinity of orthosteric ligands, as suggested by in silico studies.
type 2 orexin receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HCRTR2 | Insomnia | OX2R knockout mice or cell lines for antagonist screening |
| HCRTR2 | Narcolepsy | Patient-derived iPSCs with OX2R mutations |
| HCRT | Narcolepsy | Orexin knockout mice |
| HCRTR2 | Apoptosis | Cell lines overexpressing OX2R treated with orexin |
| HCRTR2 | Sleep-wake regulation | Conditional knockout mice |
Insomnia and Sleep Disorders
Dysregulation of orexin signaling is strongly associated with insomnia and other sleep disorders. OX2R antagonists such as lemborexant are approved for the treatment of insomnia, acting by blocking the binding of orexin to OX2R. The binding function of OX2R is therefore directly relevant to the pharmacological management of sleep disorders.
Narcolepsy
Narcolepsy type 1 is caused by the loss of orexin-producing neurons, leading to reduced orexin levels and impaired signaling through OX2R. Although the primary defect is in ligand production, the binding of residual orexin to OX2R is critical for maintaining wakefulness, and OX2R agonists are being explored as therapeutic options.
Apoptosis and Cell Death
Orexin-induced apoptosis is mediated specifically through OX2R, as demonstrated in cellular models. The seven-transmembrane domain of OX2R is essential for this effect, linking the binding event to programmed cell death pathways. This suggests that OX2R binding may have roles beyond neuromodulation, potentially in cancer or neurodegenerative contexts.
From type 2 orexin receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does OX2R mediate orexin-induced apoptosis? | OX2R knockout cell lines |
| What is the role of OX2R in sleep regulation? | OX2R knockout mice |
| How do point mutations in HCRTR2 affect ligand binding? | Point-mutation knock-in cell lines |
| Can we visualize OX2R trafficking? | Tagged knock-in of HCRTR2 with fluorescent protein |
| What is the effect of OX2R overexpression? | Overexpression cell lines |
| Which genes are downstream of OX2R activation? | CRISPR library screening in OX2R-expressing cells |
How to Study the type 2 orexin receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radioligand binding | Binding affinity and receptor density | Mapping OX2R distribution |
| Molecular dynamics | Atomic-level ligand-receptor interactions | Studying activation mechanisms |
| In silico screening | Virtual binding affinity | Identifying new modulators |
| In vitro assays | Functional activity (e.g., calcium flux) | Validating modulators |
| CRISPR knockout | Loss-of-function effects | Determining OX2R necessity |
| CRISPR knock-in | Effects of specific mutations | Structure-function studies |
| RNA-seq | Transcriptional changes | Downstream signaling pathways |
| Proteomics | Protein expression and modifications | Receptor interactome |
Radioligand Binding Assays
Radioligand binding assays using selective antagonists such as radiolabeled EMPA allow quantification of OX2R binding sites in tissues and cells. This method has been used to map OX2R distribution in rodent brain and peripheral tissues.
Molecular Dynamics Simulations
Microsecond molecular dynamics simulations can reveal atomic-level interactions between OX2R and ligands, including non-canonical Gq activation mechanisms. These simulations complement experimental structural studies.
In Silico and In Vitro Screening
Virtual screening followed by in vitro validation is a powerful approach to identify new OX2R modulators. This strategy has been used to discover novel compounds with potential therapeutic applications.
CRISPR-Based Functional Genomics
CRISPR knockout, point mutation, and knock-in models enable precise interrogation of OX2R function in cells and animals. These models are essential for linking specific residues or domains to ligand binding and downstream signaling.
How CRISPR Can Be Used to Study GO:0031772 type 2 orexin receptor binding
Knockout
CRISPR knockout of HCRTR2 can abolish OX2R expression, allowing researchers to test the requirement for OX2R in orexin-induced responses such as apoptosis or sleep regulation. Knockout cell lines are valuable for identifying off-target effects of OX2R modulators.
Point Mutation
Introducing specific point mutations in HCRTR2 via CRISPR can reveal residues critical for ligand binding or G-protein coupling. For example, mutations in the binding pocket can alter affinity for orexin or synthetic antagonists.
Knock-in
Knock-in of tagged OX2R (e.g., fluorescent protein) enables real-time imaging of receptor trafficking and localization. This approach can also be used to humanize the receptor in model organisms for drug testing.
Overexpression
Overexpression of OX2R in cell lines can enhance signaling responses and facilitate biochemical studies. This is particularly useful for studying apoptosis induction by orexin, which requires sufficient receptor levels.
How EDITGENE Supports type 2 orexin receptor binding Research
Researchers studying type 2 orexin receptor binding-related genes often need to determine whether a candidate gene is causally involved in receptor function, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout and point mutation to knock-in and overexpression models, as well as library screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for type 2 orexin receptor binding research.
Frequently Asked Questions About type 2 orexin receptor binding
What is GO:0031772?
GO:0031772 is the Gene Ontology term for type 2 orexin receptor binding, a molecular function describing the binding of a ligand to the type 2 orexin receptor (OX2R).
What genes are involved in type 2 orexin receptor binding?
The primary gene is HCRTR2, which encodes OX2R. Other genes include HCRT (orexin ligands) and G-protein subunits such as GNAQ and GNAI1.
What is the function of type 2 orexin receptor binding?
It initiates signaling cascades that regulate sleep-wake states, arousal, and energy balance, and can also induce apoptosis in certain contexts.
Which diseases are associated with type 2 orexin receptor binding?
Insomnia, narcolepsy, and potentially conditions involving apoptosis dysregulation.
How can I study type 2 orexin receptor binding?
Using radioligand binding assays, molecular dynamics simulations, in vitro screening, and CRISPR-based models.
What are the endogenous ligands for OX2R?
Orexin-A and orexin-B are the endogenous neuropeptides that bind and activate OX2R.
What is the difference between OX1R and OX2R binding?
OX2R couples to both pertussis toxin-sensitive and -insensitive G-proteins, while OX1R couples exclusively to pertussis toxin-insensitive G-proteins.
Can CRISPR be used to study OX2R function?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models are powerful tools for dissecting OX2R function.
What cell lines express OX2R?
The SK-N-MC cell line expresses an orexin binding site distinct from OX1R, and many recombinant cell lines overexpress OX2R for studies.
What are the therapeutic implications of OX2R binding?
OX2R antagonists like lemborexant are used for insomnia, and agonists are being explored for narcolepsy.
Conclusion
Type 2 orexin receptor binding (GO:0031772) is a fundamental molecular function that governs critical physiological processes, particularly sleep-wake regulation. The interaction between orexin peptides and OX2R triggers diverse signaling pathways through dual G-protein coupling, with implications for sleep disorders, apoptosis, and beyond. Advances in structural biology, molecular dynamics, and CRISPR-based models continue to unravel the intricacies of this binding event, offering new opportunities for therapeutic intervention. As research progresses, a deeper understanding of OX2R binding will undoubtedly lead to improved treatments for insomnia, narcolepsy, and other related conditions.
References
- 2. Dragan P et al.. 2025. Non-canonical G(q) activation by orexin receptor type 2 and lemborexant observed in microsecond molecular dynamics simulations.. Sci Rep 15(1):30899 PMID: 40846858
- 3. Voisin T et al.. 2006. Orexin-induced apoptosis: the key role of the seven-transmembrane domain orexin type 2 receptor.. Endocrinology 147(10):4977-84 PMID: 16857748
- 4. Janockova J et al.. 2018. Investigation of New Orexin 2 Receptor Modulators Using In Silico and In Vitro Methods.. Molecules 23(11) PMID: 30423961
- 5. Mitsukawa K et al.. 2022. Orexin 2 receptor (OX2R) protein distribution measured by autoradiography using radiolabeled OX2R-selective antagonist EMPA in rodent brain and peripheral tissues.. Sci Rep 12(1):8473 PMID: 35589803
- 6. Kim WJ et al.. 2024. Emerging and upcoming therapies in insomnia.. Transl Clin Pharmacol 32(1):1-17 PMID: 38586124
- 7. Zhu Y et al.. 2003. Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins.. J Pharmacol Sci 92(3):259-66 PMID: 12890892
- 8. Wieland HA et al.. 2002. The SK-N-MC cell line expresses an orexin binding site different from recombinant orexin 1-type receptor.. Eur J Biochem 269(4):1128-35 PMID: 11856342
